LPA1R inhibitors (Bristol Myers Squibb/Inception Sciences/PharmAkea)

N/A

Report date: 2025/06/11 20:01:15
NME

Base Information

Drug NameLPA1R inhibitors (Bristol Myers Squibb/Inception Sciences/PharmAkea)
Drug Alias Namelysophosphatidic acid receptor type 1 inhibitors (Bristol Myers Squibb/Inception Sciences/PharmAkea)BMT-053011
ClassificationSmall molecules
Mechanisms of ActionLysophosphatidic acid receptor Edg-2 antagonists
TargetsLysophosphatidic acid receptor Edg-2
Therapy Area/IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesInception Therapeutics IncPharmakea IncBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsMetabolic Dysfunction-Associated Steatotic Liver Disease

Other Information

ATC CodeN/A
Related LinksN/A